Zeo ScientifiX, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $10.9M
- Price
- $1.39
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.00%
- Volume
- 105
About
Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company specializing in developing biological therapeutics aimed at treating degenerative diseases and fostering regenerative medicine. Its flagship investigational product, Zofin, is an acellular biologic therapy sourced from perinatal materials. This candidate is currently in Phase I/II clinical trials, evaluating its efficacy for COVID-19, chronic obstructive pulmonary disease (COPD), and knee osteoarthritis. The company's portfolio also includes Patient Pure X, an autologous, blood-derived biologic technology designed to enhance the body's natural capacity to reduce cellular inflammation and promote tissue healing. Furthermore, Zeo ScientifiX develops and distributes products containing its proprietary ingredients for topical aesthetic applications. These offerings include ZEO GROW X, a professional-grade formula delivering concentrated topical exosomes to support follicular function, as well as ZEO GROW BOOST and EXO FOLLICLE FUEL. Founded in 2011, the company was formerly known as Organicell Regenerative Medicine, Inc. before rebranding to Zeo ScientifiX, Inc. in February 2024. It is headquartered in Davie, Florida.
Quick stats
Shares outstanding7.8M
Computed float1.1M
Float / shares13.5%
Cash runway (months)12.1
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001557376
AI Summary
AI-generated1/13
minorbullishoperations update
ZEO ScientifiX Plans Expansion into Georgia and Tennessee as New Regenerative Medicine Laws Take Effect
ZEO ScientifiX plans to expand its regenerative medicine operations into Georgia and Tennessee following each state's enactment of new laws establishing frameworks for physician-performed stem cell and regenerative therapies.
Georgia House Bill 1275 was signed May 11, 2026, and Tennessee House Bill 2246 on May 19, 2026; the company intends to support providers with regenerative biologics, physician education, and product documentation, building on its Florida footprint under that state's 2025 law.
The company itself cautions that the state laws do not constitute FDA approval and that providers remain responsible for compliance with federal law, licensing rules, and standards of care.
No financial terms, investment amounts, or revenue expectations were disclosed; CEO Ian Bothwell framed the move as building a scalable national platform as additional states adopt similar frameworks.
Red flags
- Expansion is 'planned' only -- no committed capital, headcount, or revenue expectations disclosed
- Filer is a clinical-stage, pre-commercial OTCQB micro-cap; expansion economics are unproven
- Release expressly notes state laws do not constitute FDA approval and do not displace federal law
- Supporting physician use of non-FDA-approved regenerative biologics is a compliance-sensitive area the release itself acknowledges